头颈癌围手术期免疫治疗的电车难题

文献信息

中文摘要

背景： 随着KEYNOTE-689试验的发表，围手术期免疫治疗已成为局部晚期头颈癌治疗的新范式，该试验表明在手术和风险适应性辅助治疗基础上加用新辅助和辅助帕博利珠单抗可改善无事件生存期。尽管这些结果代表了一个数十年来鲜有实质性进展的领域的重要进步，但在真实世界医疗系统中实施该策略可能带来非预期后果。在头颈癌诊疗高度区域化的加拿大背景下，围手术期免疫治疗可能通过额外会诊、生物标志物检测以及在根治性手术前进行全身治疗而显著延长从诊断到治疗的时间间隔。治疗启动延迟本身与较差的肿瘤学结局相关，并可能缩小部分患者获得治愈性切除的窗口。除进展为不可切除外，围手术期延迟还可能导致手术升级，需要更广泛的切除，从而对言语、吞咽和生活质量造成重大功能后果。这些结局难以在传统试验终点中捕捉，但仍与患者和临床医生高度相关。KEYNOTE-689中观察到的生存获益似乎主要由远处复发减少所驱动，这提出了一个重要的临床问题：为防止全身性复发，可接受的局部区域并发症程度是多少。最近发表的NIVOPOSTOP试验提供了一种可能更为保守的策略，即引入术后免疫治疗而不延迟手术。最终，挑战不在于是否应该取得进步，而在于如何在已经受延迟和有限资源制约的系统中实施这一进步。额外的真实世界和IV期证据对于确定哪些患者从围手术期免疫治疗中获得净获益以及如何将该策略安全整合到临床实践中至关重要。

英文摘要

Perioperative immunotherapy has emerged as a new therapeutic paradigm in the management of locally advanced head and neck cancer following the publication of the KEYNOTE-689 trial, which demonstrated improved event-free survival with the addition of neoadjuvant and adjuvant pembrolizumab to surgery and risk-adapted adjuvant therapy. While these results represent important progress for a field that has seen few meaningful advances in decades, implementation of this strategy within real-world health-care systems may introduce unintended consequences. In the Canadian context, where head and neck cancer care is highly regionalized, perioperative immunotherapy may significantly lengthen the diagnosis-to-treatment interval through additional consultations, biomarker testing, and systemic therapy administration prior to definitive surgery. Delays in treatment initiation are themselves associated with worse oncologic outcomes and may narrow the window for curative resection in some patients. Beyond progression to unresectability, perioperative delay may also lead to surgical escalation, requiring more extensive resections associated with major functional consequences for speech, swallowing, and quality of life. These outcomes are difficult to capture within traditional trial endpoints yet remain highly relevant to patients and clinicians. The survival benefit observed in KEYNOTE-689 appeared largely driven by a reduction in distant recurrence, raising an important clinical question regarding the acceptable degree of locoregional morbidity to prevent systemic relapse. The recently published NIVOPOSTOP trial offers a potentially more conservative strategy by introducing postoperative immunotherapy without delaying surgery. Ultimately, the challenge is not whether progress should occur, but how it should be implemented within systems already constrained by delays and limited resources. Additional real-world and phase IV evidence will be essential to identify which patients derive net benefit from perioperative immunotherapy and how this strategy can be integrated safely into clinical practice.